Trastuzumab Clinical Trials

2 recruiting

Trastuzumab Trials at a Glance

7 actively recruiting trials for trastuzumab are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Beijing, Guangzhou, and Hangzhou. Lead sponsors running trastuzumab studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, and Blokhin's Russian Cancer Research Center.

Browse trastuzumab trials by phase

About Trastuzumab Clinical Trials

Looking for clinical trials for Trastuzumab? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Trastuzumab trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Trastuzumab clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Trastuzumab EmtansineCancer of BreastTrastuzumab Deruxtecan
Seoul National University Hospital100 enrolled1 locationNCT06928818
Recruiting
Phase 2

Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan

Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT07537673
Recruiting

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

HER2-low Breast CancerHER2-positive Breast CancerTrastuzumab-rezetecan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300 enrolled1 locationNCT07358182
Recruiting
Not Applicable

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

HER2-positive Breast CancerTrastuzumab Deruxtecan
Blokhin's Russian Cancer Research Center60 enrolled1 locationNCT07281001
Recruiting

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Breast CancerBreast Cancer MetastaticBreast Carcinoma+9 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano500 enrolled1 locationNCT07030569
Recruiting
Not Applicable

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

CDK4/6 InhibitorChemotherapeutic ToxicityTrastuzumab+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences148 enrolled1 locationNCT06197581
Recruiting
Phase 2

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Advanced Breast CancerObjective Response RateTrastuzumab Emtansine
The First Affiliated Hospital with Nanjing Medical University36 enrolled1 locationNCT06125834